SpaceX Stock Could Soar by 73%, According to a Wall Street Analyst

Morgan Stanley analyst Adam Jonas reiterated an overweight rating and set a $300 price target for SpaceX, citing growth-adjusted valuation; the bullish call helped catalyze a share jump earlier in the week. SpaceX reported quarterly revenue up 92% year over year to $7.8 billion and a $541 million net loss, versus a $1 billion loss a year earlier, while completing Starship’s first successful orbital test flight and signing AI compute deals including one worth $1.11 billion per month. The article warns that the valuation depends on uncertain Starship progress, regulatory timing and AI monetization, and its author advises staying away from the stock at current levels.

Analysis

The central valuation risk is not simply whether SpaceX can grow, but whether multiple businesses can deliver on a shared execution chain: Starship progress supports lower launch costs and broader connectivity/AI ambitions. A setback could therefore impair several valuation narratives at once, while success may take years to convert into cash flow. That creates unusually asymmetric sensitivity to milestone news at a price that already requires substantial execution.

Near term, an analyst upgrade can extend momentum, but it is not evidence that the bullish growth-adjusted comparison is robust. The reported AI compute agreement should be tested against contract duration, counterparties, capacity deployment, revenue recognition, and cash collection; headline contract value alone does not establish monetization. Likewise, improving losses alongside rapid revenue growth matters less if investment needs or launch costs absorb the economics.

Over 1–3 months, watch regulatory approvals, Starship test cadence, and quarterly evidence that AI commitments become recognized revenue. Over 6–18 months, repeatable operations and segment-level cash generation—not a single successful test—would validate the interconnected-business thesis. The contrarian point is that the analyst target may be directionally right while still understating timing and execution risk: a delay can compress the multiple before reported results deteriorate. No clean pair trade follows from the article; the named mega-cap comparisons do not establish equivalent business exposures or relative value.

Key Decisions for Investors

• Do not chase the analyst-driven rally. For existing SPCX exposure, trim into strength or keep sizing modest until operating milestones and cash conversion support the valuation; the falsifier is sustained execution across Starship and monetization rather than another bullish target.
• Treat the AI compute agreement as a diligence trigger, not booked economics. Verify contract terms, customer concentration, deployment capacity, recognized revenue, and collections in the next disclosures; absent confirmation, discount headline commitments in valuation work.
• For investors needing downside protection, consider a defined-risk SPCX put spread only if option liquidity and implied volatility make the premium acceptable; avoid an outright short without borrow and positioning data. Reassess after Starship regulatory or test updates and quarterly results.
• Thesis invalidation on the cautious side: repeatable Starship progress, timely approvals, and disclosed AI revenue/cash contribution would weaken the execution-risk discount and argue against trimming further. A material test or regulatory delay, or failure of contracted AI activity to appear in reported revenue, strengthens the downside case.